Navigation Links
Northwestern researchers investigate treatment for tumor cells in spinal fluid
Date:8/6/2012

In two to five percent of women with breast cancer, tumor cells migrate into the spinal fluid invading the tissue surrounding the brain and spinal cord called the meninges. While a rare complication, the condition is challenging because there is no agreed-upon standard of treatment, leaving little hope for patients affected. Northwestern Medicine researchers are currently examining a novel approach to delivering an FDA approved drug that they hope will advance research for this type of cancer and lead to discoveries that may improve outcomes in the future.

As part of the clinical trial, the drug Trastuzumab is directly injected into the spinal fluid in hopes of stopping the growth of the cancer cells in patients with HER-2 positive breast cancer. Jeffrey Raizer, MD, co-director of the Northwestern Brain Tumor Institute (NBTI), is the principal investigator for trial which he developed. NBTI is part of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital.

"When cancer spreads to the spinal fluid and tissues surrounding the brain, called leptomeningeal metastases (LM), there are very limited therapeutic options," said Raizer, who is also medical director of neuro-oncology at Northwestern Memorial and associate professor of neurology at Northwestern University Feinberg School of Medicine. "This rare condition typically occurs in later stages of cancer and often the benefits of treatment are small and may be counteracted by its side effects. For women with HER-2 positive breast cancer, they often have well-controlled disease in their body when this complication occurs."

Raizer explains that drugs cannot easily penetrate from the blood stream into the spinal fluid because of the blood brain barrier, making the condition difficult to treat. In this trial, the antibody will be delivered directly into the spinal fluid using a device that is placed under the scalp called an Ommaya reservoir. A small catheter is inserted into a fluid-filled space allowing fluid to be removed and for the drug to be instilled into it.

Women with HER-2 positive breast cancer that has spread to their spinal fluid are currently being enrolled in the clinical trial. HER-2 is a type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 and leads to an excess of HER-2 protein. This type of breast cancer tends to be more aggressive compared to other breast cancers. Trastuzumab is currently approved for intravenous administration for treatment of HER-2 positive breast cancers and has been shown to be effective in slowing growth of these cancer cells while decreasing the risk of recurrence. Researchers hope similar findings will be true for its use in the treatment of LM.

"We want to offer patients the best chance of recovery possible," said Raizer. "By injecting the drug directly into the brain and spinal fluid, we hope to be able to offer a better means of treating the cancer in the spinal fluid."

The trial will enroll up to 30 women at five sites around the country. Participants must be 18 years old and have HER-2 positive breast cancer that has spread to the spinal fluid. Participants will be assigned to one of four groups receiving dosages of the drug to test its safety and effectiveness and then the safe dose level will be expanded.

"Research trials like this are an important means of finding better treatments for conditions that currently have very few options," added Raizer


'/>"/>
Contact: Megan McCann
memccann@nmh.org
312-926-5900
Northwestern Memorial Hospital
Source:Eurekalert

Related medicine news :

1. Northwestern Medicine hosts the National Marfan Foundations Annual Conference
2. Northwestern launches comprehensive program for patients with bicuspid aortic valve disease
3. Vanderbilt researchers find proteins may point way to new prostate cancer drug targets
4. MDC researchers develop new approach to treat acute liver failure
5. Breast Cancer Charity Overstates Value of Mammograms: Researchers
6. Boston University researchers expand synthetic biologys toolkit
7. Global health researchers urge integrating de-worming into HIV care in Africa
8. Researchers find potential cancer roadblock
9. CWRU School of Medicine researchers discover gene that permanently stops cancer cell proliferation
10. Boys impulsiveness may result in better math ability, say MU researchers
11. Accelerated resolution therapy significantly reduces PTSD symptoms, researchers report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement ... Vice President of North American Capital Sales at HTG Molecular . ... in the commercialization of the HTG EdgeSeq system and associated reagents in North America. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: